Clinical Trials Logo

Clinical Trial Summary

Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system (CNS) occurring in immunocompromised patients. Recovery of JC virus (JCV) specific T cell immune responses is the only available therapeutic option. JCV may use immune checkpoint inhibitory pathways to evade immune responses. The aim of this project is to determine whether T cell expression of immune checkpoint molecules is correlated to antiviral T cell responses, control of JCV replication and PML outcome. Immune checkpoint blockade by reversing T cell exhaustion may represent a therapeutic perspective for PML.


Clinical Trial Description

PML is a devastating orphan disease of the CNS due to the reactivation of JCV in immunocompromised patients. Given the lack of drugs controlling JCV replication, initiation of antiretroviral therapy in HIV-infected patients or cessation of immunosuppressive therapies in others, and subsequent recovery of JCV-specific T cell immune responses remains to date the only available therapeutic option. Promoting antiviral immune responses may improve the control of viral replication and the outcome of this severe disease. Immune checkpoint molecules such as PD-1 are inhibitory receptors expressed on T cells that trigger inhibitory signaling pathways, limiting effector immune responses in cancer and chronic infections. Immune checkpoint inhibitory pathways implicated in evading immune responses may be at play in PML. Immune checkpoint blockade using monoclonal antibodies targeting PD-1, by reversing T cell exhaustion, has been suggested as a therapeutic perspective for PML. More insights in the dynamics of immune checkpoint molecules expressed by T cells in PML patients are needed to pave the way for a therapeutic study. The aim here is to determine whether T cell expression of a broad range of immune checkpoint molecules, and its dynamics, correlates with the generation of antiviral of immune responses, the control of JCV replication and PML outcome. To this end the investigators will recruit 15 PML patients from 4 teaching hospitals in the South West of France and assess at PML diagnosis and 1, 3 and 6 months after, the expression of immune checkpoint molecules on circulating T cells, ex vivo specific immune responses against a JCV peptide library, JC viral load in cerebrospinal fluid, blood and urine, and clinical and neuroradiological outcomes. ;


Study Design


Related Conditions & MeSH terms

  • Leukoencephalopathies
  • Leukoencephalopathy, Progressive Multifocal
  • Progressive Multifocal Leukoencephalopathy

NCT number NCT04453917
Study type Interventional
Source University Hospital, Toulouse
Contact Guillaume MARTIN-BLONDEL
Phone 5 61 77 96 99
Email martin-blondel.g@chu-toulouse.fr
Status Recruiting
Phase N/A
Start date February 23, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Terminated NCT01211639 - Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy N/A
Completed NCT02004444 - JC Virus Reactivation in Multiple Sclerosis N/A
Recruiting NCT05849467 - Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy Phase 1
Recruiting NCT01730131 - Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Recruiting NCT04781309 - NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy Early Phase 1
Completed NCT02694783 - Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Early Phase 1
Completed NCT01132053 - Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
Completed NCT03399981 - Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Terminated NCT00746941 - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Phase 1/Phase 2
Completed NCT02895581 - Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy N/A
Not yet recruiting NCT05541549 - A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML Phase 2
Recruiting NCT04091932 - Treatment of PD-1 Inhibitor in AIDS-associated PML Phase 2
Not yet recruiting NCT06276504 - Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Phase 2/Phase 3